Research Associate
Publications
A cell-active cyclic peptide targeting the Nrf2/Keap1 protein-protein interaction.
– Chemical Science
(2023)
14,
10800
(doi: 10.1039/d3sc04083f)
Development of constrained peptide inhibitors targeting an oncogenic E3 ubiquitin ligase
(2023)
(doi: 10.1101/2023.04.27.535981)
Front Cover: Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance (ChemMedChem 2/2023)
– ChemMedChem
(2023)
18,
(doi: 10.1002/cmdc.202200703)
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance
– ChemMedChem
(2022)
18,
e202200548
(doi: 10.1002/cmdc.202200548)
A fragment-based approach leading to the discovery of inhibitors of CK2α with a novel mechanism of action
– RSC medicinal chemistry
(2022)
13,
1420
(doi: 10.1039/d2md00161f)
Development of small cyclic peptides targeting the CK2α/β interface.
– Chem Commun (Camb)
(2022)
58,
4791
(doi: 10.1039/d2cc00707j)
Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.
– Molecules (Basel, Switzerland)
(2021)
26,
1977
(doi: 10.3390/molecules26071977)
Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).
– Chemical Society Reviews
(2021)
50,
1480
(doi: 10.1039/d0cs00556h)
Chemical probes targeting the kinase CK2: a journey outside the catalytic box.
– Organic & Biomolecular Chemistry
(2021)
19,
4380
(doi: 10.1039/d1ob00257k)
General dual functionalisation of biomacromolecules via a cysteine bridging strategy
– Organic & biomolecular chemistry
(2020)
18,
4224
(doi: 10.1039/d0ob00907e)
- 1 of 3